Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Kansas
Headquarters: Lawrence, KS, United States of America
Website: http://www.ku.edu
Year Founded: 1865
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 28, 2024
Emerging Company Profile
Vandria: renewing mitochondria to treat CNS, muscle and other diseases
Swiss biotech Vandria is restoring energy balance in neurons with its first program, soon to enter the clinic for mild cognitive impairment
BioCentury | Apr 9, 2022
Finance
April 8 Quick Takes: Kaleido winding down operations
Plus: BioCryst loses $1.2B in market cap after pivotal pause and the latest in CEPI investments and more
BioCentury | Jun 13, 2020
Translation in Brief
OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more
BioCentury’s roundup of preclinical news
BioCentury | Mar 29, 2019
Targets & Mechanisms
Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment
A look at new and emerging targets at AACR 2019 and their mechanisms
BioCentury | Mar 15, 2019
Product Development
Broadening the PARP playing field
How the PARP field is mapping out new synthetic lethality plays
BioCentury | Jan 25, 2019
Company News
Notable Labs grants Cures Within Reach commercial rights to pediatric leukemia compound
BioCentury | Dec 14, 2015
Product Development
Risk-benefit litmus test
How Zafgen could find an approval path after a second death in beloranib trials
Items per page:
1 - 10 of 60